Verastem Oncology (VSTM)

Executive Summary

Verastem Oncology is a commercial-stage biopharmaceutical company focused on developing novel small molecule therapies targeting the RAS/MAPK signaling pathway, which drives approximately 30% of all human cancers. The company's lead asset, avutometinib, a first-in-class RAF/MEK clamp, received FDA approval in combination with defactinib for the treatment of KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC), establishing a new standard of care in this high-unmet-need indication. Verastem is leveraging its deep understanding of RAS pathway biology to expand the therapeutic potential of avutometinib across multiple tumor types through rational combination strategies, including ongoing trials in LGSOC and other RAS-driven cancers. The company's robust pipeline includes a Phase 3 registrational trial (RAMP 301) evaluating avutometinib plus defactinib in frontline LGSOC, as well as earlier-stage programs in KRAS-mutant non-small cell lung cancer (NSCLC) and other solid tumors, positioning Verastem for long-term growth in the precision oncology space. With a strong cash position and a disciplined commercial strategy, Verastem is poised to capture significant market share in the RAS-mutant oncology market, projected to exceed $10 billion annually.

Upcoming Catalysts (preview)

• Q3 2026Top-line data from Phase 2 RAMP 201 trial of avutometinib + defactinib in recurrent LGSOC85% success
• Q4 2026Initial safety and efficacy data from Phase 1/2 trial of avutometinib + defactinib in KRAS-mutant NSCLC60% success
• H1 2027Regulatory update on potential label expansion for avutometinib + defactinib in first-line LGSOC based on RAMP 301 interim analysis70% success